Main Menu

This invention includes the generation and use of a polyclonal antibody for synapse-associated protein 102 (SAP102) and a polyclonal antibody that binds to mGluR7 when phosphorylated at Serine 862. Peptides of the sites were generated and injected into rabbits to create an immune response. Serum was collected from the rabbits that was then affinity purified. The specificity of the resulting polyclonal antibodies was then determined using biochemical techniques.

This invention includes the generation and use of polyclonal antibodies that specifically recognize the glutamate receptor 1 protein that has been phosphorylated at Serine 567 (GluA1 pS567). Glutamate receptors are ligand-gated ion channels and are the predominant excitatory neurotransmitter receptor type in humans. A peptide sequence on the gene was selected surrounding the phosphorylation site. This peptide was then generated and injected into rabbits to create an immune response. Serum was then collected from the rabbit and the antibodies were affinity purified.

This invention includes the generation and use of monoclonal antibodies that specifically recognize either arginine vasopressin (AVP) or oxytocin (OT) when bound to neurophysins. The neurophysins (NPs) are a family of proteins that bind to hormones as they are released from the hypothalamus and make their way to the pituitary gland. Monoclonal antibodies were generated that specifically recognize vasopressin bound to a neurophysin (NP-AVP) or oxytocin bound to a neurophysin (NP-OT). Seven monoclonal antibodies were characterized.

This technology includes the creation and use of a polyclonal antibody for Neuroligin-4, NLGN4, that was created by injecting a peptide surrounding the pT707 phosphorylation site into rabbits and affinity purifying the resulting serum. Neuroligin-4 is a member of the neuroligin family of cell adhesion proteins. This family has been shown to play a role in the maturation and function of the neuronal synapse and has been implicated in patients with autism and intellectual disability.

This technology includes a therapeutic approach to prevent secondary edema after cerebrovascular hemorrhage. Using an animal model, we found that edema is triggered by massive extravasation of myelomonocytic cells from the blood into the brain in response to hemorrhaging vessels. Administration of anti-LFA1 and anti-VLA4 antibodies resulted in an inhibition of extravasation of the myelomonocytic cells. This single dose treatment prevented secondary edema and markedly improved functional outcomes if administered within the first six hours following cerebrovascular hemorrhage.

This technology includes the development and use of the VA-17 antibody that detects both amidated and extended forms of Oxytocin in radioimmunoassay. This antibody can be used for in vitro work, including RIA assays, to detect both forms of Oxytocin: amidated and extended.

This technology includes the generation and use of novel rabbit polyclonal antibodies against a GST-tagged portion of the human protein mitofusin 1 (amino acids 667-741).

This technology includes a sensitive and specific method to rapidly detect antibodies in biofluids. This assay has been used for the detection of antibodies in blood, urine, and saliva. Until now, no one has used LIPS to detect clinically relevant antibodies to SARS-CoV-2 Nucleocapsid (N) or Spike (S) in saliva. Briefly, LIPS employs recombinantly synthesized target proteins or peptides (e.g., S and N proteins) tagged with light-emitting proteins as targets to be captured by host produced immunoglobulins. These immunoglobulins can be captured by protein A/G beads and immobilized.

This technology includes a mouse model for studying SiP1 receptor signaling for development of therapeutics for a variety of conditions. The S1P1 receptor locus of the mouse has been modified by gene targeting to encode a fusion of the S1P1 receptor and the tetracycline-controlled activator protein (tTA) connected by a Tobacco Etch Virus (TEV) cleavage sequence, internal ribosome initiation sequence (IRES), followed by a beta-arrestin-Tobacco Etch Virus (TEV) protease fusion protein. When activated, the modified S1P1 receptor binds the beta-arrestin-TEV protease fusion, which cleaves the tTA.

This technology includes a cell line secreting an IgG monoclonal antibody to mouse ZP2 which is useful to detect mouse ZP2 on immunoblot, immunohistology and immunoprecipitation, and prevents female fertility if administered IP in mice.